SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY772

SYRE·Spyre Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
SPY007 is still in preclinical development, and the SPY772 coformulation has not yet entered clinical testing. The Phase 2 SKYLIGHT surrogate trial's topline data is expected in late 2027 or early 2028. If positive, the coformulation would still need to enter and complete clinical trials before any potential approval, putting commercialization several years away.
Why 3/10
SPY772 has no hard, dated binary catalyst within the next ~12 months; the next milestone is topline Week 16 data from the Phase 2 SKYLIGHT trial, expected in late 2027 or early 2028. The program is early-stage (SPY007 still preclinical) and represents one of several pipeline programs at Spyre, which has a market cap suggesting the stock is primarily driven by the more advanced IBD assets (SPY001, SPY002, SPY003).
Actionable Insight NEUTRAL

SPY772 has no near-term catalyst; the next meaningful event is the SKYLIGHT Phase 2 topline readout in late 2027 or early 2028. For investors tracking Spyre, the more immediate catalysts are the ongoing SKYLINE Part B combination data (SPY001/SPY002/SPY003 pairwise combinations in IBD) and the company's progress toward pivotal studies. SPY772 is a long-duration option on HS expansion that will not resolve for over a year.

Price Chart

Loading chart...

Executive Summary

SPY772 is a preclinical/early Phase 2 combination program from Spyre Therapeutics (NASDAQ: SYRE) that pairs two long-acting antibodies: SPY072 (anti-TL1A) and SPY007 (anti-IL-17A/F) for hidradenitis suppurativa (HS). The program was launched in August 2026 alongside the initiation of the Phase 2 SKYLIGHT surrogate trial. SPY007 has not yet been tested in humans, and topline data from SKYLIGHT is not expected until late 2027 or early 2028. Spyre has a strong cash position (~$1.5B pro forma) and a broad pipeline of IBD and immunology assets, but SPY772 is an early-stage, non-binary program for the foreseeable future. The stock trades near $99 with a strong analyst consensus (21 Buy/Strong Buy) and a mean price target of $122.53, implying ~23% upside.

How It Works

SPY772 is a combination of two engineered antibodies designed to be given together as a single shot. One antibody (SPY072) blocks TL1A, a protein that drives inflammation in the gut and skin. The other (SPY007) blocks IL-17A and IL-17F, two related inflammatory signals. By hitting two different inflammatory pathways at once, the combination aims to deliver stronger and more durable symptom control than blocking either pathway alone, with the convenience of infrequent dosing.

Trial Status

SPY772 was launched in August 2026 as a combination program pairing SPY072 (anti-TL1A, already in Phase 2 for rheumatoid arthritis) with SPY007 (anti-IL-17A/F, still preclinical). The Phase 2 SKYLIGHT trial in hidradenitis suppurativa (HS) began enrolling in August 2026. The trial is a randomized, placebo-controlled proof-of-concept study (n~150) evaluating dual inhibition of TL1A and IL-17A/F. The primary endpoint is the proportion of patients achieving HiSCR75 response at Week 16. The trial design uses SPY072 in patients initiating bimekizumab as a surrogate proof-of-concept for the eventual SPY772 coformulation.

The Two-Sided Case

▲ Bull Case4
SPY772 targets two validated inflammatory pathways (TL1A and IL-17A/F) in hidradenitis suppurativa, a disease with limited treatment options and significant unmet need.
Spyre has a strong balance sheet with approximately $1.5 billion in pro forma cash as of September 30, 2026, providing runway into the second half of 2029 to fund the SPY772 program and broader pipeline.
The SKYLIGHT trial uses a clever, capital-efficient surrogate design (evaluating SPY072 alongside bimekizumab) to generate proof-of-concept data before committing to the full coformulation.
Spyre's core IBD pipeline (SPY001, SPY002, SPY003) has already generated positive proof-of-concept data, validating the company's antibody engineering platform and reducing overall pipeline risk.
▼ Bear Case5
SPY772 is an early-stage combination program; SPY007 is still preclinical and has never been tested in humans, adding significant development risk.
Topline data from the Phase 2 SKYLIGHT trial is not expected until late 2027 or early 2028, more than 12 months away, meaning no near-term binary catalyst for this program.
SPY072, one of the two components, produced mixed results in its Phase 2 rheumatoid arthritis sub-study (statistically significant but missed internal benchmarks), raising questions about the TL1A mechanism in non-IBD indications.
The company faces competition from approved HS therapies (adalimumab, secukinumab, bimekizumab) and other developers pursuing TL1A and IL-17 pathways.
Insider sales by the CEO and other executives in October 2026 (all under 10b5-1 plans) and elevated short-sale volume (66.2% of off-exchange volume on November 4, 2026) suggest some near-term caution among informed market participants.

Upcoming Catalysts

  • Topline Week 16 HiSCR75 data from Phase 2 SKYLIGHT trial expected late 2027 or early 2028

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 10

Hover a chip for the title
1 markets.financialcontent.com2 biospace.com3 spyre.com4 biotechdistilled.substack.com5 msn.com6 markets.businessinsider.com7 nasdaq.com8 biospace.com9 stocktitan.net10 sec.gov